EGFR and glioma: For instance, via the use of combined genetic and pharmacologic interventions (e.g., gefitinib, erlotinib, lapatinib and cetuximab), it was discovered that EGFR-associated gliomas were not responsive to EGFR tyrosine kinase inhibitors, but could inhibit EGFR-related autophosphorylation[81].